Global Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market

The prostate cancer drugs refer to drugs that are used for the prevention and treatment of prostate cancer. Prostate cancer is one of the most common types of cancer caused due to uncontrollable development of cells in the prostate gland in men that produces the seminal fluid that nourishes and transports sperm. Some of the possible treatments for prostate cancer include hormonal therapy, chemotherapy, immunotherapy, and targeted therapy. The different types of prostate cancer drugs are hormone-sensitive prostate cancer and hormone-refractory prostate cancer. Hormone-refractory prostate cancer (HRPC) is a kind of prostate cancer that no longer responds to hormone therapy, even newer treatments. The different types of therapies include hormonal therapy, chemotherapy, immunotherapy, and targeted therapy and involve various sectors such as hospitals, clinics, and others. The prostate cancer drugs market research report is one of a series of new reports from The Business Research Company that provides prostate cancer drugs market statistics, including prostate cancer drugs industry global market size, regional shares, competitors with a prostate cancer drugs market share, detailed prostate cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the prostate cancer drugs industry. This prostate cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global prostate cancer drugs market size will grow from $17.63 billion in 2022 to $18.81 billion in 2023 at a compound annual growth rate (CAGR) of 6.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global prostate cancer drugs market size is expected to grow to $23.50 billion in 2027 at a CAGR of 5.7%. The increasing men geriatric population is a major driver for the prostate cancer drugs market. Prostate cancer is one of the most common types of cancer in men aged above 60. According toACL(Administration For Community Living), a US-based government organization,the geriatric population is expected to increase by 21.6% by 2040. Among those population, men are affected more with prostate camcer than women.For example, in January 2022, according to American Cancer Society, a US-based organization, prostate cancer develops in older men and in non-hispanicblack menand about 6 cases in 10 are diagnosed in men who are 65 or older(geriatric population). Therefore, increasing men geriatric population drives the prostate cancer market.. Recurrent/non-responsive prostate cancer is a major restraint for the growth of the prostate cancer drugs market. This is because recurrent/non-responsive prostate cancer cells lead to recurrence or spread of cancer after initial treatment. Prostate cancer can recur locally in the tissue next to the prostate, the surrounding lymph nodes in the pelvis or lymph nodes outside this area, tissues next to the prostate (such as the muscles that help control urination, the rectum, or the wall of the pelvis). Cancer can also travel through the bloodstream and recur in bones or other organs. According to the American Society of Clinical Oncology (ASCO), around 50% to 95% of men in the US with high-risk prostate cancer experience recurrence after localized treatment. The use of combination therapy to treat prostate cancer is an emerging trend in the market. This is mainly because, in some cases of prostate cancer, monotherapy has not been effective for the patients. In this regard, companies in the prostate cancer drugs market are investing more in combination therapy for the treatment of prostate cancer. For example, Pfizer announced the results of its Phase 3 PROSPER trial in patients with non-metastatic (M0) Castration-Resistant Prostate Cancer (CRPC), which show that the use of XTANDI (enzalutamide) in combination with androgen deprivation therapy (ADT) significantly reduced the risk of developing metastases or death by 71% compared to using ADT alone. Similarly, other combination therapies such as a combination of radiation therapy and androgen deprivation therapy for men with recurrent prostate cancer, and using chemotherapy drug docetaxel (Taxotere) along with ADT are also being used to treat prostate cancer. The prostate cancer drugs market in the USA is regulated by the FDA which is responsible for the approval of new drugs and lays down regulations related to the treatment of prostate cancer. For instance, the FDA approved Erleada (apalutamide) for the treatment of prostate cancer that has not spread (non-metastatic) but continues to grow despite treatment with hormone therapy (castration-resistant). This was the first case of FDA-approved treatment for non-metastatic, castration-resistant prostate cancer, and more such approvals are expected to follow in the future. Hence, the regulatory scenario related to prostate cancer drugs will encourage more drug manufacturers to enter the market. In June 2021, Bayer, a Germany-based pharmaceutics company acquired Noria Therapeutics Inc. (Noria) and PSMA Therapeutics Inc. for an undisclosed amount. With this acquisition, Bayer will gain exclusive access to a specialized alpha radionuclide investigational drug built on actinium-225 and a small molecule aimed against prostate-specific membrane antigen. PSMA Therapeutics Inc. is a US-based company that specializes in prostate-specific membrane antigen research and Noria Therapeutics Inc. is a radiotherapy firm focused on creating alpha-emitting radiopharmaceuticals for targeted therapeutic and imaging applications in oncology. Major players in the prostate cancer drugs market are Astellas Inc., AstraZeneca PLC., Johnson & Johnson, Sanofi S.A, Bayer AG, Roche, Abbott, Pfizer, Norvaris and F. Hoffmann-La Roche AG. North America was the largest region in the prostate cancer drugs market in 2022. Middle East is expected to be the fastest-growing region in the global prostate cancer drugs market during the forecast period. The regions covered in the global prostate cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the prostate cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The prostate cancer drugs market consists of sales of Abiraterone Acetate, Apalutamide, and Bicalutamide. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global prostate cancer drugs market is segmented - 1) By Type: Hormone Sensitive Prostate Cancer, Hormone Refractory Prostate Cancer 2) By Therapy: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy 3) By End User: Hospitals, Clinics, Other End-Users

RFID tags are small devices with a chip and an antenna that may be used to wirelessly identify the objects they are attached to by using an RFID reader. RFID tags transmit their identification, track, and communicate information to adjacent readers through radio waves, and can store a variety of data ranging from a single serial number to multiple pages of information. It uses that use hardware and software technologies that allow users to receive, store, and transmit data through radio frequency waves. The main types of radio-frequency identification (RFID) tags are active RFID and passive RFID. The active RFID tags are battery-powered sensor tags that connect to various access points throughout an area (such as a building) and transfer data to the cloud. Active RFID is frequently used in real-time location tracking. The different materials include plastic, paper, glass, others and operate in various frequencies such as low frequency, high frequency, ultra-high frequency. It is used in several applications including agriculture, retail and wholesale, healthcare, BFSI, transpiration and logistics, education, and others. The radio-frequency identification (RFID) tags market research report is one of a series of new reports from The Business Research Company that provides radio-frequency identification (RFID) tags market statistics, including radio-frequency identification (RFID) tags industry global market size, regional shares, competitors with a radio-frequency identification (RFID) tags market share, detailed radio-frequency identification (RFID) tags market segments, market trends and opportunities, and any further data you may need to thrive in the radio-frequency identification (RFID) tags industry. This radio-frequency identification (RFID) tags market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global radiofrequency identification (RFID) tags market size grew from $10.3 billion in 2022 to $11.46 billion in 2023 at a compound annual growth rate (CAGR) of 11.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The radiofrequency identification (RFID) tags market size is expected to grow to $15.72 billion in 2027 at a CAGR of 8.2%. The rising e-commerce and online retail sales are expected to propel the growth of the RFID tags market in the forecast period. E-commerce (electronic commerce) is the buying and marketing of goods and services over a computer network, most often the internet, as well as the exchange of payments and information. RFID technology gives e-commerce organizations a better picture of the supply chain, allowing them to find what they need to fulfill a customer's request. For instance, according to the United Nations Conference on Trade and Development (UNCTAD) report, a Switzerland-based intergovernmental organization for trade and development, in 2020, the worldwide share of sales of online retail increased from 16% in 2019 to 19% in 2020. Therefore, the rising e-commerce and online retail sales drive the growth of the RFID tags market. RFID companies are increasingly implementing advanced technologies such as IoT and Big Data which is a growing trend in the market. With the help of IoT, RFID tags can connect objects into a network and make them create and send data. It assists in the real-time monitoring of tagged objects and the creation of a system of connected devices that broadcast information about their position, conditions, and quantities in real-time. For instance, in February 2020, Omni-ID, a US-based company operating in passive industrial radio frequency identification (RFID) tags, introduced a new range of Bluetooth Low Energy (BLE) and Long Range (LoRa) enabled IoT devices that utilize a comprehensive set of sensors with the ability to transmit situational and status data using Radiofrequency Identification (RFID) tags to enhance asset Management & Logistics process in an organization. In May 2022, HID Global, a US-based manufacturer of secure identity products acquired Vizinex RFID for an undisclosed amount. Through this acquisition, HID Global aims to expand its RFID tag portfolio in healthcare/medical, manufacturing, oil & gas, data centers, and others. Vizinex RFID is a US-based company operating in RFID tags. Major players in the radiofrequency identification (RFID) tags market are Avery Dennison, Zebra Technologies, Honeywell, NXP Semiconductors, Impinj Inc., Invengo Technology Pte. Ltd., ams AG, Atmel Corp, Alien Technology, Smartrac N.V., GAO RFID Inc., The Tag Factory, and MOJIX. North America was the largest region in the radio-frequency identification (RFID) tags market in 2022. The regions covered in the radiofrequency identification (RFID) tags report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the radiofrequency identification (RFID) tags market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The radiofrequency identification (RFID) tags market consists of sales scanning antenna, a transceiver and a transponder.Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global radiofrequency identification rfid tags market is segmented - 1) By Tag Type: Active RFID, Passive RFID 2) By Material: Plastic, Paper, Glass, Other Materials 3) By Frequency: Low Frequency, High Frequency, Ultra High Frequency 4) By Application: Agriculture, Retail And Wholesale, Healthcare, BFSI, Transpiration And Logistics, Education, Other Applications

Tumor ablation therapy devices are minimally invasive devices used in the treatment of tumors, commonly of kidney, liver and lung. The main technologies in the tumor ablation therapy devices are radiofrequency ablation, microwave ablation, cryoablation, irreversible electroporation ablation, and others. Irreversible electroporation (IRE) in tumor ablation therapy is a new tissue ablation method in which micro to millisecond electrical pulses are supplied to undesirable tissue to produce cell necrosis by irreversible cell membrane permeabilization. The treatments included are surgical, laparoscopic, and percutaneous that are used in various applications such as kidney cancer, liver cancer, breast cancer, lung cancer, prostate cancer, and others. The various end-users of tumor ablation therapy devices are hospitals, oncology clinics, and others. The tumor ablation therapy devices market research report is one of a series of new reports from The Business Research Company that provides tumor ablation therapy devices market statistics, including tumor ablation therapy devices industry global market size, regional shares, competitors with a tumor ablation therapy devices market share, detailed tumor ablation therapy devices market segments, market trends and opportunities, and any further data you may need to thrive in the tumor ablation therapy devices industry. This tumor ablation therapy devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global tumor ablation therapy devices market grew from $0.56 billion in 2022 to $0.64 billion in 2023 at a compound annual growth rate (CAGR) of 15.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The tumor ablation therapy devices market is expected to grow from $1.1 billion in 2027 at a CAGR of 14.4%. The increasing prevalence of cancer is a key factor driving the growth of the tumor ablation therapy devices market. Cancer is considered to be the second major cause of death, with around 1 in 6 deaths due to cancer worldwide. Tumor ablation is a minimally invasive procedure widely used in the treatment of lung, liver, kidney, and bone tumors. For instance, in 2020, according to the American Institute of cancer research, there were an estimated 18.1 million cancer cases around the world. It was estimated that 9.3 million cases were in men and 8.8 million in women. Among them, lung and breast cancers are the most common cancers in the world, and about 12.5% and 12.2% of the new cases are diagnosed in 2020. The procedure is an effective method for patients who have failed chemotherapy or radiotherapy, thereby supporting the growth of the tumor ablation therapy devices market. Product recalls of tumor ablation devices due to technical issues are expected to hinder the growth of the tumor ablation therapy devices market. The companies are retrieving their products from the market due to safety concerns. For instance, COVIDien Emprint Long Percutaneous Antenna with Thermosphere Technology, a tumor ablation device from Medtronic had recalled its devices due to the disengagement of ceramic trocar tip of the Emprint ablation from the needle shaft post-ablation. Similarly, in June 2018, Accurian RF Ablation by Medtronic Sofamor Danek USA Inc. was recalled due to the difficulty in insertion. The product recalls caused a financial burden on the companies hindering the tumor ablation therapy devices market. Major companies operating in the tumor ablation therapy devices are focusing on technology advancements for shorter procedures, increased safety, lower exposure to radiation, faster learning curves, and improved outcomes J&J medicals have released a microwave ablation system called NEUWAVE, which is the first minimally invasive device to put electrodes into cancer cells and thereby increase the temperature around them for burning the cancer cells. In June 2020, Boston Scientific has launched a technology called DirectSense technology, a tool used for monitoring the effect of radiofrequency (RF) now for cardiac procedures, which may be further employed for tumors. In August 2022, Imagin Medical, a Canada-based urologic oncology company acquired enCAGE Coil™ Precision Ablation System for Prostate Cancer from TROD Medical NV for $2.5m. The acquisition would strengthen Imagin’s position as a urologic oncology company and expand its portfolio in the field of prostate cancer. TROD Medical NV is a Belgium-based medical device company. Major players in the tumor ablation therapy devices market are Galil Medical Inc., Misonix Inc., HealthTronics, Angiodynamics, Boston Scientific Corporation, Medtronic PLC., EDAP TMS S.A, Neuwave Medical Inc., BVM Medical Limited, and Erbe Elektromedizin GmbH. North America was the largest region in the tumor ablation therapy devices market in 2022. Asia-Pacific was the second largest region in the global tumor ablation therapy devices market. The regions covered in the global tumor ablation therapy devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the tumor ablation therapy devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The tumor ablation therapy devices market consists of sales of radiofrequency ablation, microwave ablation, cryoablation, irreversible electroporation ablation, and others that are used for tumor ablation therapies. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global tumor ablation therapy devices market is segmented - 1) By Technology: Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation, Other Technologies 2) By Treatment: Surgical, Laparoscopic, Percutaneous 3) By End User: Hospitals, Oncology Clinics, Other End Users 4) By Application: Kidney Cancer, Liver Cancer, Breast Cancer, Lung Cancer, Prostate Cancer, Other Applications

Urology medical lasers are used in the treatment of medical conditions related to the urniary system such as urinary stones, benign prostatic hyperplasia (BPH). The main types of urology medical lasers are the holmium laser system, diode laser system, thulium laser system, and others. The holmium laser system is the process of removing stones in the bladder, kidneys, ureters, or urethra using lasers. The applications involved are benign prostatic hyperplasia (bph), urolithiasis, non-muscle-invasive bladder cancer (nmibc), and others. The end-users involved are hospitals, clinics, and others. The urology medical lasers market research report is one of a series of new reports from The Business Research Company that provides urology medical lasers market statistics, including urology medical lasers industry global market size, regional shares, competitors with a urology medical lasers market share, detailed urology medical lasers market segments, market trends and opportunities, and any further data you may need to thrive in the urology medical lasers industry. This urology medical lasers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global urology medical lasers market size will grow from $0.97 billion in 2022 to $1.01 billion in 2023 at a compound annual growth rate (CAGR) of 4.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The urology medical lasers market size is expected to grow from $1.23 billion in 2027 at a CAGR of 5.0%. Rising cases of urological disorders contribute to the demand for the urology medical lasers market. Growing urological cases including bladder cancer and prostate diseases among others are boosting the demand for minimally invasive surgeries and related devices. According to the American Institute for Cancer Research’s statistics on bladder statistics, bladder cancer is the sixth most common cancer in men and the 17th most common cancer in women. The surge in urological diseases and conditions increases the demand for urological surgeries and supports the growth of the urology medical lasers market. Product innovation is a key trend gaining popularity in the urology medical lasers market. The product innovations assist urologists in achieving better outcomes and deliver diagnostic, therapeutic and minimally invasive procedures to improve clinical outcomes, reduce overall costs and enhance quality of life for patients. For example, in June 2020, Olympus®, a Japanese manufacturer of optics and reprography products, announces the commercial launch of the Soltive™ SuperPulsed Laser System (Soltive Laser System), a new application of thulium fiber laser technology designed for stone lithotripsy and soft tissue applications. Major players operating in the market are continuously focusing on developing new products incorporating advanced technology to meet the requirement of medical professionals. For instance, in June 2020, Olympus Corporation, a Japanese manufacturer of innovative medical and surgical products, launched the Soltive SuperPulsed Thulium Fiber Laser System designed for stone lithotripsy and soft tissue applications in urology. The SuperPulsed thulium fiber laser dust stones into very fine particles faster than other laser systems. In September 2021, Boston Scientific, a US-based biomedical engineering company, acquired Lumenis ltd for an undisclosed amount. The acquisition would integrate Lumenis’s laser portfolio into Boston Scientific’s kidney stone management and benign prostatic hyperlapsia offerings. Lumenis is a Israel-based manufacturer of energy-based medical solutions. Major players in the urology medical lasers market are Olympus Corporation, Ethicon Inc., Stryker Corporation, Boston Scientific Corporation, Richard Wolf GmbH, Cook Medical Incorporated, Karl Storz SE & Co. KG, Lumenis Ltd., Becton Dickinson and Company, and OmniGuide Holdings Inc. North America was the largest region in the urology medical lasers market in 2022. Asia-Pacific was the second largest region in the global urology medical lasers market report. The regions covered in the global urology medical lasers marke report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the urology medical lasers market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The urology medical lasers market consists of sales of holmium laser system, diode laser system, thulium laser system, and others. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from goods and/or services sold within the specified market and geography through sales, grants, or donations in terms of currency (in USD ($) unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global urology medical lasers market is segmented - 1) By Laser Type: Holmium Laser System, Diode Laser System, Thulium Laser System, Other Laser Types 2) By Application: Benign Prostatic Hyperplasia (BPH), Urolithiasis, Non-Muscle-Invasive Bladder Cancer (NMIBC), Other Applications 3) By End User: Hospital, Clinic, Other End Users

Nephrology and urology devices are used in the diagnosis and treatment of kidney and genitourinary diseases. The main types of nephrology and urology devices are dialysis devices and equipment, urinary stone treatment devices and equipment, urinary incontinence and pelvic organ prolapse devices and equipment, benign prostatic hyperplasia (BPH) treatment devices and equipment, and endoscopy devices and equipment. Dialysis devices and equipment is a machines used in dialysis that filter a patient's blood to remove excess water and waste products when the kidneys are damaged, dysfunctional, or missing. The dialysis machine itself is an artificial kidney. The type of expenditure is public and private. The products used are instruments/equipment and disposables. The various end-users are hospitals and clinics, diagnostic laboratories, and others. The nephrology and urology devices market research report is one of a series of new reports from The Business Research Company that provides nephrology and urology devices market statistics, including nephrology and urology devices industry global market size, regional shares, competitors with a nephrology and urology devices market share, detailed nephrology and urology devices market segments, market trends and opportunities, and any further data you may need to thrive in the nephrology and urology devices industry. This nephrology and urology devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global nephrology and urology devices market grew from $17.37 billion in 2022 to $18.63 billion in 2023 at a compound annual growth rate (CAGR) of 7.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The nephrology and urology devices market is expected to grow to $23.52 billion in 2027 at a CAGR of 6.0%. The increase in the patient pool due to the rising geriatric population globally contributed significantly to the growth of the nephrology and urology devices market during the historic period. According to the World Health Organization, the number of people aged 60 years and above was 1 billion in 2020 and the number will rise to 1.4 billion by 2030 and it will reach 2.1 billion by 2050. This rise in the geriatric population increased the demand for medical care and drove the healthcare expenditure. These factors increased the demand for these products and drove the market during the historic period. The nephrology and urology devices market was limited by the shortage of skilled workforce in most developed and developing countries, during the historic period. Equipment fabrication and integration require specialized skillsets relating to life sciences, pharmaceuticals, electronics, and software. These skillsets are available to a limited number of organizations, most of which are located in the USA and Europe. This shortage of skilled labour was a significant deterrent to the growth of the market during the historic period. The nephrology and urology market is witnessing a rise in new product launches. Due to the high competition in the market, many companies are investing in advanced technologies to widen product portfolios and increase their share in the market. For instance, in March 2020, Medi-Tate an Israel-based medical device company received authorization for iTind system that is used to implant and remove nitinol devices during bladder neck remodelling. Researchers at Washington University in St. Louis, the University of Illinois at Urbana-Champaign, and Northwestern University together developed a wireless implant to control overactive bladder using LED lights. Major companies in the nephrology and urology devices market include Baxter International Inc., Fresenius Medical Care AG & Co KGaA, Cook Group Incorporated, B. Braun Group, C. R. and Bard Inc. North America was the largest region in the global nephrology and urology devices market in 2022. Asia-Pacific was the second largest region in the global nephrology and urology devices market. The regions covered in the nephrology and urology devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the nephrology and urology devices market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa., South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The nephrology and urology devices market consist of sales of instruments such as ureteral catheters, PCN catheters, urinary stents, stone baskets, urology guidewires, and renal dilators that are used to treat kidney and genitourinary diseases. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global nephrology and urology devices market is segmented - 1) By Type: Dialysis Devices And Equipment, Urinary Stone Treatment Devices And Equipment, Urinary Incontinence & Pelvic Organ Prolapse Devices And Equipment, Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment, Endoscopy Devices And Equipment 2) By End User: Hospitals And Clinics, Diagnostic Laboratories, Other End Users 3) By Type of Expenditure: Public, Private 4) By Product: Instruments/Equipment, Disposables

Bioabsorbable stents are tubes inserted into blood vessels to unblock passageways and dissolve in the body after a period of time. The main products of bioabsorbable stents are polymer-based bioabsorbable stents and metal-based bioabsorbable stents. Bioresorbable stents (BRS) or vascular scaffolds are coronary stents that can fully dissolve in the body. It is also segmented by absorption rate into slow-absorption stents and fast-absorption that are used in various applications such as coronary artery diseases, and peripheral artery diseases. The bioabsorbable stents market research report is one of a series of new reports from The Business Research Company that provides bioabsorbable stents market statistics, including bioabsorbable stents industry global market size, regional shares, competitors with a bioabsorbable stents market share, detailed bioabsorbable stents market segments, market trends and opportunities, and any further data you may need to thrive in the bioabsorbable stents industry. This bioabsorbable stents market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global bioabsorbable stents market grew from $0.31 billion in 2022 to $0.34 billion in 2023 at a compound annual growth rate (CAGR) of 9.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The bioabsorbable stents market is expected to grow from $0.49 billion in 2027 at a CAGR of 9.2%. Increasing cardiovascular diseases is a key factor driving the growth of the bioabsorbable stents market. Cardiovascular disorders are the leading cause of death across the world and 4 out of 5 cardiovascular deaths are caused by strokes and heart attacks. Moreover, one-third of such deaths occur prematurely in people under the age of 70. Bioresorbable stents are built primarily to reduce these risks of late complications, such as scaffold thrombosis or restenosis, that can happen when a conventional metal stent's rigid metal backbone remains permanently rooted in the diseased vessel. According to the American Heart Association, it is estimated that more than 23.6 million die due to cardiovascular diseases by 2030. Therefore, increasing cardiovascular diseases are expected to drive the growth of the bioabsorbable stents market. The risks associated with bioabsorbable stents restrain the growth of the market. The high risks with stents force companies to withdraw their devices from the market reducing the revenues from bioabsorbable stents. For instance, Abbott had to withdraw its product Absorb and Boston Scientific terminated their Renuvia scaffold development program as the devices showed a high risk of myocardial infarction and thrombosis. This was due to the non-uniform structure of the polymer used in the stents that makes the device susceptible to large deformation and causes flow disruption. The drug-eluting stent (DES) is gaining significant popularity in the bioabsorbable stents market. The drug-eluting stent (DES) device was designed to avoid the regeneration of tissue that would otherwise obstruct the artery and this was a new step forward in the treatment of peripheral artery disease. Boston Scientific launched its self-expanding drug-eluting stent (DES) peripheral artery disease (PAD) scheme which helped the company to expand its PAD portfolio. Major players in the bioabsorbable stents market are Abbott Laboratories, Reva Medical, Elixir Medical Corporation, Biotronik SE & Co. KG, Amaranth Medical Inc., Zorion Medical, Tepha, Inc., S3V Vascular Technologies, ICON Interventional Systems, and Arterius Limited. North America was the largest region in the bioabsorbable stents market in 2022. Western Europe was the second largest region in the global bioabsorbable stents market report. The regions covered in global bioabsorbable stents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the bioabsorbable stents market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The bioabsorbable stents market consists of sales of polymer-based bioabsorbable stents and metal-based bioabsorbable stents. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global bioabsorbable stents market is segmented - 1) By Product Type: Polymer-based Bioabsorbable Stents, Metal-based Bioabsorbable Stents 2) By Absorption Rate: Slow- absorption stents, Fast- absorption Stents 3) By Applications: Coronary Artery Diseases, Peripheral Artery Diseases

Medical equipment are devices that can be instrument, apparatus or machine that can be used in the prevention, diagnosis or treatment of illness or disease, or for detecting, measuring, restoring, correcting or modifying the structure or function of the body for health purpose. The main types of medical equipment are in-vitro diagnostics, dental equipment and supplies, ophthalmic devices, diagnostic imaging equipment, cardiovascular devices, hospital supplies, surgical equipment, orthopedic devices, patient monitoring devices, diabetes care devices, nephrology and urology devices, ENT devices, anesthesia and respiratory devices, neurology devices, and wound care devices. In-vitro diagnostics are tests done on samples like blood or tissue that is taken from the human body. In-vitro diagnostics will detect diseases or other conditions and are used to monitor a person’s overall health to cure, treat, or prevent diseases. The type of expenditure involved is public and private. The various product are instruments/equipment and disposables. The various end users involved are hospitals and clinics, homecare, diagnostics centres, and others. The medical equipment market research report is one of a series of new reports from The Business Research Company that provides medical equipment market statistics, including medical equipment industry global market size, regional shares, competitors with a medical equipment market share, detailed medical equipment market segments, market trends and opportunities, and any further data you may need to thrive in the medical equipment industry. This medical equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global medical equipment market grew from $639.75 billion in 2022 to $695.05 billion in 2023 at a compound annual growth rate (CAGR) of 8.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The medical equipment market is expected to grow to $922.39 billion in 2027 at a CAGR of 7.3%. The rise in sedentary jobs, busy lifestyles, and changing consumer preferences are affecting the disease profile of the world population, especially non-communicable diseases such as cancer, diabetes, and cardiovascular diseases. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of chronic diseases such as diabetes. According to the World Health Organization, chronic disease prevalence is expected to rise by 57% globally, by the year 2020. This is increasing the demand for medical devices used in the diagnosis, prognosis, and treatment of several diseases, thereby driving the demand for medical equipment. These factors are expected to increase the patient pool globally, thereby driving the market during the forecast period. Regulatory changes are likely to lead to increased costs relating to new product development and service offerings to clients. These changes are related to customer data protection such as the European Union's General Data Protection Regulation (GDPR), changes to equipment approval procedures, and other regulatory changes. For instance, according to cookieyed data 2021, in the US, PwC reported that 68% of 200 businesses surveyed intended to spend between $1 million and $10 million to comply with GDPR regulations. The GDPR regulation is an EU law on data protection and privacy of individuals residing in the European Union and the European Economic Area (EEA). It also regulates the export of personal data outside the EU and EEA areas. Additionally, the FDA is requesting more clinical data to support claims, therefore increasing the time to process 510(k)s by over 55% over the last decade. The potential loss of revenue due to delays in product release and additional costs incurred due to stringent approval processes puts a strain on investments relating to new product development, thereby affecting the growth of the medical equipment market. Device performance and patient data are available to healthcare service providers and are helping them to improve patient monitoring and overall care quality. Some companies are integrating medical device data with EMR (Electronic Medical Records) to improve transparency and collaboration. As consumer wearables are becoming more common, patient data volumes are increasing and companies are investing in deploying data management, warehousing, and security technologies. For example, Medtronic launched a tool to augment their cardiac devices to securely transfer device data to doctors and allow them to monitor the critical health indicators of their patients. Major companies in the medical equipment market include Medtronic Inc., Abbott Laboratories, Johnson & Johnson, Cardinal Health, Inc., Becton Dickinson, Siemens AG, STRYKER CORPORATION, Koninklijke Philips N.V., F. Hoffmann-La Roche Ltd., and Boston Scientific Corporation. North America was the largest region in the global medical equipment market in 2022. Asia-Pacific was the second largest region in the global medical equipment market. The regions covered in the medical equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the medical equipment market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa., South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The medical equipment market consists of sales of devices used in the diagnosis, treatment and monitoring of medical conditions. The market includes diagnostic devices, imaging devices, surgical devices and patient monitoring devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global medical equipment market is segmented - 1) By Type: In-Vitro Diagnostics, Dental Equipment And Supplies, Ophthalmic Devices, Diagnostic Imaging Equipment, Cardiovascular Devices, Hospital Supplies, Surgical Equipment, Orthopedic Devices, Patient Monitoring Devices, Diabetes Care Devices, Nephrology And Urology Devices, ENT Devices, Anesthesia And Respiratory Devices, Neurology Devices, Wound Care Devices 2) By Type of Expenditure: Public, Private 3) By Product: Instruments/Equipment, Disposables 4) By End User: Hospitals And Clinics, Homecare, Diagnostics Centers, Other End Users Subsegments Covered: Point-of-Care Diagnostics Devices And Equipment, Immunochemistry Diagnostic Devices And Equipment, Clinical Chemistry Diagnostics Devices And Equipment, Molecular Diagnostics Devices And Equipment, Microbiology Diagnostic Devices And Equipment, Hemostasis Diagnostic Devices And Equipment, Hematology Diagnostic Devices And Equipment, Immunohematology Diagnostic Devices And Equipment, Therapeutic Dental Equipment, General Dental Devices And Equipment, Dental Diagnostic Imaging Devices And Equipment, Dental Surgical Devices And Equipment, Vision Care Devices And Equipment, Cataract Surgery Devices And Equipment, Refractive Surgery Devices And Equipment, Diagnostic And Monitoring Ophthalmic Devices And Equipment, X-Ray Systems Devices And Equipment, Ultrasound Systems Devices And Equipment, Computed Tomography (CT) Scanners Devices And Equipment, Magnetic Resonance Imaging Systems Devices And Equipment, Cardiovascular Monitoring And Diagnostic Devices And Equipment, Nuclear Imaging Devices And Equipment, Cardiovascular Surgery Devices And Equipment, Cardiac Rhythm Management (CRM) Devices And Equipment, Interventional Cardiology Devices And Equipment, Defibrillator Devices And Equipment, Peripheral Vascular Devices And Equipment, Prosthetic Heart Valve Devices And Equipment, Electrophysiology Devices And Equipment, Cardiac Assist Devices And Equipment, Disposable Hospital Supplies, Sterilization Equipment And Disinfectants, Mobility Aids And Transportation Equipment, Operating Room Equipment, Surgical Sutures And Staples, Handheld Surgical Devices And Equipment, Electrosurgical Devices And Equipment, Joint Reconstruction Devices And Equipment, Spinal Surgery Devices And Equipment, Trauma Fixation Devices And Equipment, Orthobiologics Devices And Equipment, Arthroscopy Devices And Equipment, Orthopedic Braces And Support Devices And Equipment, Craniomaxillofacial (CMF) Devices And Equipment, Orthopedic Prosthetics, Orthopedic Accessories,, Fetal And Neonatal Monitoring Devices, Weight Monitoring And Body Temperature Monitoring Devices And Equipment, Vital Parameter Monitoring Devices And Equipment, Remote Patient Monitoring Devices And Equipment, Blood Glucose Test Strips, Insulin Pens, Syringes, Pumps And Injectors, Lancing Devices And Equipment, Continuous Glucose Monitoring Devices And Equipment, Blood Glucose Meters, Dialysis Devices And Equipment, Urinary Stone Treatment Devices And Equipment, Urinary Incontinence & Pelvic Organ Prolapse Devices And Equipment, Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment, Endoscopy Devices And Equipment, Hearing Aid Devices And Equipment, Hearing Diagnostic Devices And Equipment, ENT Surgical Devices And Equipment, Hearing Implants, Voice Prosthesis Devices And Equipment, Nasal Splints, Respiratory Devices And Equipment (Therapeutic And Diagnostic), Anesthesia Machines, Anesthesia Disposables, Respiratory Disposables, Cerebrospinal Fluid Management (CSF) Devices And Equipment, Interventional Neurology Devices And Equipment, Neurosurgery Devices And Equipment, Neurostimulation Devices, Traditional Adhesive Dressings, Negative-pressure Wound Therapy (NPWT), Traditional Gauze Dressings, Advanced Wound Care Devices

Intracranial stents are tubular device that is placed inside the blood vessel, canal, or duct. They are used for intracranial stenosis and brain aneurysms to open the blocked arteries. The main types of intracranial stents are self-expanding stents, balloon expanding stents, and stent-assisted coil embolization. A self-expanding stent expands on its own after being inserted into the lumen it is meant to occupy, such as a blood vessel, tube, or organ. Balloon expanding stents also known as balloon-expandable stents have higher radial stiffness and more accurate placement and are designed to treat restenosis in the iliac artery by opening clogged arteries and restoring blood flow. Stent-assisted coil embolization helps stabilize the coils within the aneurysm and provide a buttress that allows for coil deposition while preventing coil haerniation into the parent vessel lumen. The various indications of diseases include brain aneurysm, intracranial stenosis and are implemented in various sectors such as hospitals, ambulatory surgery centers, and others. The intracranial stents market research report is one of a series of new reports from The Business Research Company that provides intracranial stents market statistics, including intracranial stents industry global market size, regional shares, competitors with intracranial stents market share, detailed intracranial stents market segments, market trends and opportunities, and any further data you may need to thrive in the intracranial stents industry. This intracranial stents market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global intracranial stents market size grew from $0.36 billion in 2022 to $0.43 billion in 2023 at a compound annual growth rate (CAGR) of 18.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The intracranial stents market size is expected to grow to $0.73 billion in 2027 at a CAGR of 14.2%. The increase in incidence of a brain aneurysm is expected to propel the growth of the intracranial stents market in the coming years. A brain aneurysm is the development of a bulge in the blood vessels of the brain. This bulge may rupture or burst and can cause brain hemorrhage, which may lead to the death of the patient. Intracranial vessel stenting (IVS) is a minimally invasive treatment for treating serious cerebral artery stenosis. The weakening of the arteries that deliver blood to the brain is known as cerebral artery stenosis. According to the brain aneurysm foundation, by 2020, an expected 6.5 million people in the USA are suffering from an unruptured brain aneurysm, accounting for about one in every 50 people. Additionally, a brain aneurysm causes around 500,000 deaths globally every year and is more common among women. Thus, the increasing incidence of a brain aneurysm will drive the intracranial stents market growth. The introduction of flow diversion technology to the field of neurointervention has revolutionized the treatment of intracranial aneurysms which is a key trend gaining popularity in the intracranial stents market. Flow diversion is an endovascular procedure in which a device is inserted in the parent blood vessel to move blood flow away from the aneurysm rather than around the aneurysm sac. For instance, in March 2020, Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST) developed an innovative intracranial flow diverter stent for brain aneurysms treatment. Intracranial flow diverters have the benefit of becoming adaptable and flexible to the vessel's shape and direction and also helps the vessel wall recover by relieving it of the continuous burden of blood flow. It is entitled as Chitra flow diverter, the device is ready for transfer and further testing in animals to be followed by human trials. In January 2021, Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST), an autonomous institute of the Department of Science & Technology (DST), Govt of India, under the Technical Research Centre (TRC), announced that it has entered into Technology Transfer Agreements with Biorad Medisys, for two biomedical implant devices namely an Atrial Septal Defect Occluder and an Intracranial Flow Diverter Stents developed by the institute in collaboration with National Aerospace Laboratories, Bangalore (CSIR-NAL)using superelastic NiTiNOL alloys. Biorad Medisys is an India-based company that manufactures various implants and surgical devices. Major players in the intracranial stents market are Medtronic, Balt, Stryker Corporation, MicroPort Scientific Corporation, Boston Scientific Corporation, Acandis GmbH, Admedes Schuessler GmbH, MicroVention (Terumo), and Phenox. North America was the largest region in the intracranial stents market in 2022. Asia-Pacific is expected to be the fastest region in the intracranial stents market during the forecast period. The regions covered in the intracranial stents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the intracranial stents market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The intracranial stents market consists of sales of Neuroform stents, Solitaire, Enterprise, and Leo plus, and Wingspan stent. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global intracranial stents market is segmented - 1) By Type: Self Expanding Stents, Balloon Expanding Stents, Stent-Assisted Coil Embolization 2) By Disease Indication: Brain Aneurysm, Intracranial Stenosis 3) By End-User: Hospitals, Ambulatory Surgery Centers, Other End-Users